Zydus Lifesciences has achieved a significant regulatory milestone with the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Cevimeline Hydrochloride Capsules 30mg. This approval marks an important expansion of the company's pharmaceutical offerings in the competitive US market.

Product Details and Therapeutic Application

The approved medication is specifically indicated for treating dry mouth (xerostomia) associated with Sjögren's syndrome. Sjögren's syndrome is an autoimmune disorder that primarily affects the body's moisture-producing glands, leading to symptoms such as dry mouth and dry eyes. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion.

Manufacturing and Market Opportunity

The company projects annual sales of USD 26.9 million for this product based on IQVIA MAT data, indicating substantial market potential in the treatment of Sjögren's syndrome-related symptoms. The Cevimeline Hydrochloride Capsules 30mg will be manufactured at Zydus Lifesciences 's SEZ-II facility in Ahmedabad.

Regulatory Portfolio Expansion

This latest approval strengthens Zydus Lifesciences' regulatory portfolio in the United States market. The company now holds 436 approvals and has filed 505 ANDAs since commencing the filing process in FY 2003-04. The final approval status allows the company to commence commercial activities for this product in the United States market, contributing to its revenue diversification strategy.

Strategic Significance

The USFDA approval represents a valuable addition to Zydus Lifesciences' pharmaceutical portfolio, particularly in the niche market of treatments for autoimmune-related complications. This approval enhances the company's presence in specialized therapeutic segments addressing conditions that affect moisture-producing glands.

Zydus Lifesciences Limited has expanded its companion diagnostics portfolio with the launch of two innovative continuous glucose monitoring devices. The company announced on March 12, 2026, the introduction of Diasens™ and GlucoLive™, next-generation CGM systems that integrate artificial intelligence-powered analytics with comprehensive remote care capabilities.

Product Features and Technology

The new CGM devices represent a significant advancement in glucose monitoring technology for Indian patients. Unlike existing devices in the market that rely on NFC technology requiring manual scanning, Diasens™ and GlucoLive™ automatically stream glucose readings to patients' smartphones every three minutes without any manual intervention.

Strategic Partnership and Digital Integration

Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare™) to enhance the patient experience through digital integration. The CGM system connects with TatvaCare's proprietary GoodFlip™ app, creating a comprehensive healthcare ecosystem that includes:

• AI-powered report analysis and trend detection
• Personalized diet and exercise coaching
• Doctor consultation services
• Diagnostic lab booking capabilities
• Comprehensive medical record vault
• Real-time alerts for hypo-/hyperglycaemic episodes

Market Context and Healthcare Need

The launch addresses a critical healthcare challenge in India, where the country hosts over 101 million adults living with diabetes according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology. This represents the second-highest diabetes burden globally, with an additional 136 million individuals in the pre-diabetic stage.

Diabetes serves as the leading cause of Chronic Kidney Disease in India, with 25-40% of CKD patients having a diabetes history. The healthcare system currently relies on episodic monitoring through periodic finger-prick tests or laboratory HbA1c checks conducted every three to six months, creating significant gaps in continuous care.

Clinical Benefits and Remote Monitoring

The devices feature a dedicated clinician dashboard that enables healthcare providers to monitor patients remotely and make data-driven treatment adjustments. The AI analytics system detects glucose trends, flags dangerous episodes, and links fluctuations to food and activity patterns, generating actionable insights for both patients and healthcare providers.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the patient-centric approach: "The launch of Diasens™ and GlucoLive™ strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control."

Technology Integration and Care Ecosystem

The convergence of the CGM devices with TatvaCare's digital platform creates a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real-time. This integration ensures uninterrupted glucose data capture, including critical overnight readings and emergency situations, while providing early intervention capabilities through continuous remote monitoring.